Man Group PLC Jounce Therapeutics, Inc. Transaction History

Man Group PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$3.33 - $4.93 $53,579 - $79,323	-16,090 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$4.3 - $6.73 $14,452 - $22,619	-3,361 Reduced 17.28%	16,090 $80,000
Q1 2019 May 15, 2019	BUY	$3.43 - $6.87 $66,716 - $133,628	19,451 New	19,451 $121,000
Q4 2018 Feb 14, 2019	SELL	$2.69 - $6.71 $537,513 - $1.34 Million	-199,819 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$6.5 - $8.37 $1.3 Million - $1.67 Million	199,819 New	199,819 $1.3 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.